Literature DB >> 28303410

Downregulation of myogenic microRNAs in sub-chronic but not in sub-acute model of daunorubicin-induced cardiomyopathy.

Gabriel Doka1, Eva Malikova1, Kristina Galkova1, Giampiero La Rocca2, Peter Kruzliak3, Mariusz Adamek4, Luis Rodrigo5, Peter Krenek1, Jan Klimas6.   

Abstract

Cardiac muscle-related microRNAs play important roles in cardiac development and disease by translational silencing of mRNAs, the dominant mechanism of microRNA action. To test whether they could be involved in daunorubicin-associated cardiomyopathy (DACM), we determined expression patterns of myomiRs in two distinct models of DACM. We used 10-12 weeks old male Wistar rats. In the sub-acute model, rats were administered with six doses of daunorubicin (DAU-A, 3 mg/kg, i.p., every 48 h). Rats were sacrificed two days after the last dose. In the sub-chronic model, anaesthetized rats were administered a single dose of daunorubicin (15 mg/kg, i.v., DAU-C). Age-matched controls (CON) received vehicle. Rats were sacrificed eight weeks later. Left ventricular (LV) functions (LV pressure, rate of pressure development, +dP/dt and decline, -dP/dt) were measured using left ventricular catheterization. Expressions of myomiRs (miR-208a, miR-499, miR-1 and miR-133a), markers of cardiac failure (atrial and brain natriuretic peptides genes; Nppa and Nppb) and myosin heavy chain genes (Myh6, Myh7, Myh7b) in cardiac tissue were determined by RT-PCR. Protein expression of gp91phox NADPH oxidase subunit was detected by immunoblotting. Both DAU groups exhibited a similar depression of LV function, and LV weight reduction, accompanied by an upregulation of natriuretic peptides, and a decrease of Myh6 to total Myh ratio (-18% in DAU-A and - 25% in DAU-C, as compared to controls; both P < 0.05). DAU-C, but not DAU-A rats had a 35% mortality rate and exhibited a significantly increased gp91phox expression (DAU-C: 197 ± 33 versus CON-C: 100 ± 11; P < 0.05). Interestingly, myomiRs levels were only reduced in DAU-C compared to CON-C (miR-208: -45%, miR-499: -30%, miR-1: -29%, miR- and miR133a: -25%; all P < 0.05) but were unaltered in DAU-A. The lack of myomiRs expression, particularly in sub-chronic model, suggests the loss of control of myomiRs network on late progression of DACM. We suppose that the poor inhibition of mRNA targets might contribute to chronic DACM.

Entities:  

Keywords:  Anthracycline; Cardiomyopathy; Gene expression; MicroRNA; Myosin heavy chain isoforms; NADPH oxidase

Mesh:

Substances:

Year:  2017        PMID: 28303410     DOI: 10.1007/s11010-017-2999-8

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  53 in total

1.  Oxidative stress and myocardial gene alterations associated with Doxorubicin-induced cardiotoxicity in rats persist for 2 months after treatment cessation.

Authors:  Carole Richard; Steliana Ghibu; Stéphanie Delemasure-Chalumeau; Jean-Claude Guilland; Christine Des Rosiers; Marianne Zeller; Yves Cottin; Luc Rochette; Catherine Vergely
Journal:  J Pharmacol Exp Ther       Date:  2011-09-20       Impact factor: 4.030

2.  Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy.

Authors:  Youyou Zhao; Declan McLaughlin; Emma Robinson; Adam P Harvey; Michelle B Hookham; Ajay M Shah; Barbara J McDermott; David J Grieve
Journal:  Cancer Res       Date:  2010-09-30       Impact factor: 12.701

3.  Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure.

Authors:  Rusty L Montgomery; Thomas G Hullinger; Hillary M Semus; Brent A Dickinson; Anita G Seto; Joshua M Lynch; Christianna Stack; Paul A Latimer; Eric N Olson; Eva van Rooij
Journal:  Circulation       Date:  2011-09-06       Impact factor: 29.690

4.  Heart rate correction of the QT duration in rats.

Authors:  Jana Kmecova; Jan Klimas
Journal:  Eur J Pharmacol       Date:  2010-06-08       Impact factor: 4.432

5.  Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy.

Authors:  Longhu Li; Genzou Takemura; Yiwen Li; Shusaku Miyata; Masayasu Esaki; Hideshi Okada; Hiromitsu Kanamori; Ngin Cin Khai; Rumi Maruyama; Atsushi Ogino; Shinya Minatoguchi; Takako Fujiwara; Hisayoshi Fujiwara
Journal:  Circulation       Date:  2006-01-31       Impact factor: 29.690

6.  Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity.

Authors:  J A Jackson; J P Reeves; K H Muntz; D Kruk; R A Prough; J T Willerson; L M Buja
Journal:  Am J Pathol       Date:  1984-10       Impact factor: 4.307

7.  Treatment with an adenoviral vector encoding hepatocyte growth factor mitigates established cardiac dysfunction in doxorubicin-induced cardiomyopathy.

Authors:  Masayasu Esaki; Genzou Takemura; Ken-ichiro Kosai; Tomoyuki Takahashi; Shusaku Miyata; Longhu Li; Kazuko Goto; Rumi Maruyama; Hideshi Okada; Hiromitsu Kanamori; Atsushi Ogino; Hiroaki Ushikoshi; Shinya Minatoguchi; Takako Fujiwara; Hisayoshi Fujiwara
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-12-14       Impact factor: 4.733

8.  Myh7b/miR-499 gene expression is transcriptionally regulated by MRFs and Eos.

Authors:  Fan Yeung; Eunhee Chung; Martin G Guess; Matthew L Bell; Leslie A Leinwand
Journal:  Nucleic Acids Res       Date:  2012-05-25       Impact factor: 16.971

9.  Elevated miR-499 levels blunt the cardiac stress response.

Authors:  Joseph T C Shieh; Yu Huang; Jacqueline Gilmore; Deepak Srivastava
Journal:  PLoS One       Date:  2011-05-09       Impact factor: 3.240

10.  Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in β-adrenergic signaling and enhances apoptosis.

Authors:  L Roca-Alonso; L Castellano; A Mills; A F Dabrowska; M B Sikkel; L Pellegrino; J Jacob; A E Frampton; J Krell; R C Coombes; S E Harding; A R Lyon; J Stebbing
Journal:  Cell Death Dis       Date:  2015-05-07       Impact factor: 8.469

View more
  3 in total

1.  Modeling dynamics and alternative treatment strategies in acute promyelocytic leukemia.

Authors:  Gerson Hiroshi Yoshinari; Artur César Fassoni; Luis Fernando Mello; Eduardo M Rego
Journal:  PLoS One       Date:  2019-08-15       Impact factor: 3.240

2.  The Effects of Neuropeptide Y Overexpression on the Mouse Model of Doxorubicin-Induced Cardiotoxicity.

Authors:  Minttu Mattila; Mirva Söderström; Liisa Ailanen; Eriika Savontaus; Mikko Savontaus
Journal:  Cardiovasc Toxicol       Date:  2020-06       Impact factor: 3.231

3.  Disease severity-related alterations of cardiac microRNAs in experimental pulmonary hypertension.

Authors:  Zuzana Kmecova; Jana Veteskova; Katarina Lelkova-Zirova; Lenka Bies Pivackova; Gabriel Doka; Eva Malikova; Ludovit Paulis; Peter Krenek; Jan Klimas
Journal:  J Cell Mol Med       Date:  2020-05-12       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.